Top 20 life sciences deals list highlights 2025’s rebound

PharmaShots’ new “Top 20 Life Sciences Deals of 2025,” produced with DealForma data, offers a snapshot of how the sector closed out the year: fewer purely speculative bets, more emphasis on scale, and a clear appetite for transactions that can quickly add capabilities, revenue, or strategic optionality. The list itself underscores that late 2025 remained active enough to elevate deals such as Shionogi’s $2.5 billion Mitsubishi Tanabe Pharma business unit purchase into the year’s top 20. (linkedin.com)

That ranking lands against a backdrop of a stronger second half for life sciences dealmaking. DealForma’s Q1 review showed healthy activity across partnerships, M&A, funding, and IPOs early in the year, while Deloitte later reported that 2025 life sciences M&A rebounded after a cautious start, reaching 193 transactions worth $220 billion by the end of November, above 2024’s total deal value. EY’s 2026 firepower analysis similarly said life sciences companies signed about $240 billion in M&A in 2025, suggesting that buyers regained confidence as the year progressed. (dealforma.com)

The individual deals highlighted around PharmaShots’ year-end coverage help explain the pattern. Private capital stayed active, including Blackstone’s close of a $6.3 billion BXLS VI fund focused on life sciences investing. Large strategic and sponsor-backed transactions also remained central to the narrative. PharmaShots separately reported CVC Capital Partners’ proposed roughly €10.9 billion acquisition of Recordati, while Lilly announced on March 31, 2026, that it had agreed to acquire Centessa Pharmaceuticals to expand in sleep-wake disorders, in a transaction valued at up to about $7.8 billion including contingent value rights. Those examples show how buyers continued to favor assets tied to differentiated pipelines, durable commercial opportunities, or platform leverage. (pharmaceutical-technology.com)

Industry analyses point to a few common drivers. EY said looming patent expirations are pushing large drugmakers to replenish pipelines through external deals, while RD World’s summary of that report noted a sharp rise in AI-related deal value in 2025. Nature’s midyear biopharma deal review, also using DealForma data, described 2025 as a year defined by notable high-value transactions. Deloitte added that buyers increasingly targeted assets and technologies that support long-term resilience, especially in areas with clearer growth potential. (ey.com)

There doesn’t appear to be much direct expert commentary attached to the PharmaShots ranking itself beyond its framing as a data-backed summary, but the broader market commentary is fairly consistent: 2025 was a year of selective confidence. In other words, capital came back, but it concentrated around assets that could move the needle. That’s an inference from the deal data and sector analyses, rather than a direct quote from a single source. (dealforma.com)

Why it matters: For veterinary professionals, the immediate relevance is indirect but real. Veterinary medicine increasingly sits downstream from the same financing, R&D, diagnostics, and data infrastructure trends shaping the rest of life sciences. When large funds, strategics, and AI-enabled platforms attract more capital, that can influence valuation benchmarks, partnership appetite, and technology transfer into animal health. It may also affect the pace at which diagnostics, therapeutics, and digital tools move from human-health innovation models into veterinary use, especially in specialty care and chronic disease management. (rdworldonline.com)

For practices and veterinary business leaders, the practical takeaway is to watch the capital markets not just for animal health headlines, but for adjacent signals: where investors are placing long-term bets, which care models are consolidating, and how AI or specialty therapeutics are being valued. Those trends can shape everything from startup funding and referral networks to future acquisition interest in veterinary diagnostics, pharmacy, and care delivery businesses. (deloitte.com)

What to watch: In 2026, the key question is whether the momentum seen in late 2025 carries into a broader mix of transactions, including smaller platform deals and more spillover into animal health, or whether buyers stay concentrated on a relatively narrow set of high-conviction assets as patent-cliff pressure intensifies. (ey.com)